Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Sold by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. cut its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPRGet Rating) by 2.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 255,803 shares of the biopharmaceutical company’s stock after selling 5,156 shares during the quarter. Pinnacle Associates Ltd. owned about 0.88% of Esperion Therapeutics worth $1,279,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of ESPR. Marshall Wace LLP purchased a new position in Esperion Therapeutics during the 1st quarter valued at about $186,000. Royal Bank of Canada raised its position in shares of Esperion Therapeutics by 70.1% during the 2nd quarter. Royal Bank of Canada now owns 6,550 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 2,699 shares in the last quarter. Invesco Ltd. acquired a new position in Esperion Therapeutics during the second quarter worth approximately $225,000. Wells Fargo & Company MN increased its position in Esperion Therapeutics by 160.9% during the second quarter. Wells Fargo & Company MN now owns 26,990 shares of the biopharmaceutical company’s stock worth $572,000 after buying an additional 16,644 shares during the period. Finally, Morgan Stanley increased its position in Esperion Therapeutics by 258.9% during the second quarter. Morgan Stanley now owns 386,515 shares of the biopharmaceutical company’s stock worth $8,175,000 after buying an additional 278,813 shares during the period.

ESPR opened at $5.60 on Monday. Esperion Therapeutics, Inc. has a 1 year low of $3.28 and a 1 year high of $28.78. The stock has a fifty day moving average price of $4.49 and a 200 day moving average price of $6.36.

Esperion Therapeutics (NASDAQ:ESPRGet Rating) last posted its quarterly earnings data on Tuesday, February 22nd. The biopharmaceutical company reported ($1.77) EPS for the quarter, topping analysts’ consensus estimates of ($2.32) by $0.55. The business had revenue of $15.40 million during the quarter, compared to the consensus estimate of $14.48 million. During the same quarter in the previous year, the firm posted ($3.89) earnings per share. The company’s revenue for the quarter was up 60.4% on a year-over-year basis. As a group, analysts predict that Esperion Therapeutics, Inc. will post -3.6 earnings per share for the current year.

ESPR has been the topic of a number of research analyst reports. Credit Suisse Group decreased their target price on Esperion Therapeutics from $8.00 to $6.00 and set a “neutral” rating on the stock in a research report on Friday, January 14th. Northland Securities dropped their target price on Esperion Therapeutics from $10.00 to $5.00 in a research note on Wednesday, January 12th. StockNews.com initiated coverage on Esperion Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating for the company. Finally, HC Wainwright assumed coverage on Esperion Therapeutics in a research note on Thursday, March 10th. They set a “buy” rating and a $22.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $27.50.

About Esperion Therapeutics (Get Rating)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

Recommended Stories

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPRGet Rating).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.